Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer

被引：0
|
作者：
Sledge, G.
Miller, K.
Moisa, C.
Gradishar, W.
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
[2] Roche Labs Inc, Nutley, NJ USA
[3] Northwestern Univ, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    Ozcelik, M.
    Odabas, H.
    Ercelep, O.
    Yuksel, S.
    Mert, A. G.
    Aydin, D.
    Surmeli, H.
    Isik, D.
    Isik, S.
    Oyman, A.
    Ustaalioglu, B. B. Oven
    Aliustaoglu, M.
    Gumus, M.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06): : 617 - 624
  • [2] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    M. Ozcelik
    H. Odabas
    O. Ercelep
    S. Yuksel
    A. G. Mert
    D. Aydin
    H. Surmeli
    D. Isik
    S. Isik
    A. Oyman
    B. B. Oven Ustaalioglu
    M. Aliustaoglu
    M. Gumus
    [J]. Clinical and Translational Oncology, 2016, 18 : 617 - 624
  • [3] Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
    Dyar, Stephen
    Moreno-Aspitia, Alvaro
    [J]. BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2011, 5 : 239 - 246
  • [4] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Lueck, Hans-Joachim
    Luebbe, Kristina
    Reinisch, Mattea
    Maass, Nicolai
    Feisel-Schwickardi, Gabriele
    Tome, Oliver
    Janni, Wolfgang
    Aydogdu, Mustafa
    Neunhoeffer, Tanja
    Ober, Angelika
    Aktas, Bahriye
    Park-Simon, Tjoung-Won
    Schumacher, Claudia
    Hoeffkes, Heinz-Gert
    Illmer, Thomas
    Wagner, Harald
    Mehta, Keyur
    von Minckwitz, Gunter
    Nekljudova, Valentina
    Loibl, Sibylle
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 141 - 149
  • [5] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Hans-Joachim Lück
    Kristina Lübbe
    Mattea Reinisch
    Nicolai Maass
    Gabriele Feisel-Schwickardi
    Oliver Tomé
    Wolfgang Janni
    Mustafa Aydogdu
    Tanja Neunhöffer
    Angelika Ober
    Bahriye Aktas
    Tjoung-Won Park-Simon
    Claudia Schumacher
    Heinz-Gert Höffkes
    Thomas Illmer
    Harald Wagner
    Keyur Mehta
    Gunter von Minckwitz
    Valentina Nekljudova
    Sibylle Loibl
    [J]. Breast Cancer Research and Treatment, 2015, 149 : 141 - 149
  • [6] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    [J]. VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [7] Capecitabine plus bevacizumab in first line metastatic breast cancer:: an interim safety and efficacy report of the first phase of xeloda plus avastin 1st line metastatic breast cancer trial.
    Miller, K.
    Gradishar, W.
    Moisa, C.
    Sledge, G.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S103 - S103
  • [8] Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer
    Cortes-Funes, H.
    Ghanem, I.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 165 - 168
  • [9] (XELOX) capecitabine plus oxaliplatin: Clinical efficacy and safety in the first-line treatment for metastatic gastric cancer
    Manuguerra, G.
    Alu, M.
    Leonardi, V.
    Laudani, A.
    Palmisano, V.
    Pepe, A.
    Arcuri, C.
    Savio, G.
    Cusimano, M.
    Calabria, C.
    Porretto, C.
    de Bella, M. Tamburo
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 5 - 5
  • [10] (XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer
    Alu, M.
    Laudani, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Pepe, A.
    Arcuri, C.
    Cusimano, M. R.
    Calabria, C.
    Agostara, B.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 273 - 273
12345